Ipilimumab-induced toxicities and the gastroenterologist

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 4, 2015, Pages 657-666

  Cheng, Robert ^a   Cooper, Adam ^a,b   Kench, James ^a   Watson, Geoff ^a   Bye, William ^a   Mcneil, Catriona ^a,b,c   Shackel, Nicholas ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b The Chris O Brien Lifehouse   (Australia)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

Colitis; CTLA 4 antibody; Hepatitis; Immunotherapy; Ipilimumab; Melanoma

Indexed keywords

ALANINE AMINOTRANSFERASE; CODEINE; CORTICOTROPIN; ENOXAPARIN; GROWTH HORMONE; INFLIXIMAB; IPILIMUMAB; LOPERAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TESTOSTERONE; THYROTROPIN; THYROXINE; AZATHIOPRINE; CALCINEURIN INHIBITOR; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISOLONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE HEPATITIS; BONE METASTASIS; BRADYCARDIA; BRAIN METASTASIS; CASE REPORT; COLITIS; COLON BIOPSY; COLONOSCOPY; CORTICOTROPIN BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; GASTROENTEROLOGIST; GROWTH HORMONE BLOOD LEVEL; HOSPITAL READMISSION; HUMAN; HYPOPITUITARISM; IMMUNE COMPLEX NEPHRITIS; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; INGUINAL LYMPH NODE; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIMIT OF DETECTION; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTATIC MELANOMA; MIDDLE AGED; PERITONEUM TUMOR; PNEUMONIA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; REHYDRATION; SIDE EFFECT; SIGMOIDOSCOPY; SINGLE DRUG DOSE; STEROID THERAPY; SYSTEMIC THERAPY; TESTOSTERONE BLOOD LEVEL; THORAX PAIN; THYROTROPIN BLOOD LEVEL; TOXIC HEPATITIS; TREATMENT DURATION; VERY ELDERLY; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DRUG-INDUCED LIVER INJURY; MELANOMA; PATIENT CARE; SECONDARY;

ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CALCINEURIN INHIBITORS; COLITIS; DRUG-INDUCED LIVER INJURY; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; MELANOMA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PATIENT CARE TEAM; PREDNISOLONE; PULSE THERAPY, DRUG;

EID: 84924797761     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12888     Document Type: Article

References (35)

1. Sneyd MJ, Cox B. A comparison of trends in melanoma mortality in New Zealand and Australia: the two countries with the highest melanoma incidence and mortality in the world. BMC Cancer 2013; 13: 372.
2. Hodi FS, O'Day SJ, McDermott DF etal. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010; 363: 711-723.
3. Robert C, Thomas L, Bondarenko I etal. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011; 364: 2517-2526.
4. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin. Cancer Res. 2011; 17: 6958-6962.
5. Bernardo SG, Moskalenko M, Pan M etal. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res. 2013; 23: 47-54.
6. Kim KW, Ramaiya NH, Krajewski KM etal. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest. New Drugs 2013; 31: 1071-1077.
7. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 2012; 30: 2691-2697.
8. Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig. Dis. Sci. 2012; 57: 2233-2240.
9. Beck KE, Blansfield JA, Tran KQ etal. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 2006; 24: 2283-2289.
10. Slangen RM, van den Eertwegh AJ, van Bodegraven AA, de Boer N. Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab. World J. Gastrointest. Pharmacol. Ther. 2013; 4: 80-82.
11. Kahler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J. Dtsch. Dermatol. Ges. 2011; 9: 277-286.
12. Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS, Investigators MDX. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119: 1675-1682.
13. Margolin K, Ernstoff MS, Hamid O etal. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012; 13: 459-465.
14. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
15. Becker BN. Mycophenolate mofetil. Transplant. Proc. 1999; 31: 2777-2778.
16. Mehling A, Grabbe S, Voskort M, Schwarz T, Luger TA, Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J. Immunol. 2000; 165: 2374-2381.
17. Czaja AJ. Advances in the current treatment of autoimmune hepatitis. Dig. Dis. Sci. 2012; 57: 1996-2010.
18. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J. Hepatol. 2011; 55: 636-646.
19. Fallatah HI, Akbar HO. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy. Expert Rev. Gastroenterol. Hepatol. 2011; 5: 517-522.
20. Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can. J. Gastroenterol. 2010; 24: 588-592.
21. Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J. Am. Acad. Dermatol. 1997; 37: 445-449.
22. Chmiel KD, Suan D, Liddle C etal. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J. Clin. Oncol. 2011; 29: e237-240.
23. Harmankaya K, Erasim C, Koelblinger C etal. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med. Oncol. 2011; 28: 1140-1144.
24. Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J. Immunother. 2005; 28: 517-524.
25. Graziani G, Tentori L, Navarra P. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol. Res. 2012; 65: 9-22.
26. Sands BE, Anderson FH, Bernstein CN etal. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 2004; 350: 876-885.
27. Present DH, Rutgeerts P, Targan S etal. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 1999; 340: 1398-1405.
28. Targan SR, Hanauer SB, van Deventer SJ etal. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 1997; 337: 1029-1035.
29. Lord JD, Hackman RC, Moklebust A etal. Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig. Dis. Sci. 2010; 55: 1396-1405.
30. Schunemann HJ, Oxman AD, Brozek J etal. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336: 1106-1110.
31. Guyatt GH, Oxman AD, Vist GE etal. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926.
32. Atkins D, Best D, Briss PA etal. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
33. Attia P, Phan GQ, Maker AV etal. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005; 23: 6043-6053.
34. Downey SG, Klapper JA, Smith FO etal. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 2007; 13: 6681-6688.
35. Snyder A, Makarov V, Merghoub T etal. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014; 371: 2189-2199.